These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 2260347)

  • 1. Fluconazole: a new triazole antifungal agent.
    Pasko MT; Piscitelli SC; Van Slooten AD
    DICP; 1990 Sep; 24(9):860-7. PubMed ID: 2260347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluconazole: a new antifungal agent.
    Kowalsky SF; Dixon DM
    Clin Pharm; 1991 Mar; 10(3):179-94. PubMed ID: 2040125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses.
    Debruyne D
    Clin Pharmacokinet; 1997 Jul; 33(1):52-77. PubMed ID: 9250423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluconazole (Diflucan): a review.
    Zervos M; Meunier F
    Int J Antimicrob Agents; 1993; 3(3):147-70. PubMed ID: 18611557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses.
    Grant SM; Clissold SP
    Drugs; 1990 Jun; 39(6):877-916. PubMed ID: 2196167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic/pharmacodynamic profile of posaconazole.
    Li Y; Theuretzbacher U; Clancy CJ; Nguyen MH; Derendorf H
    Clin Pharmacokinet; 2010 Jun; 49(6):379-96. PubMed ID: 20481649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluconazole. Review and situation among antifungal drugs in the treatment of opportunistic mycoses of human immuno-deficiency virus infections.
    Vincent-Ballereau FN; Patey ON; Lafaix C
    Pharm Weekbl Sci; 1991 Apr; 13(2):45-57. PubMed ID: 1870943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review of fluconazole: a new triazole antifungal agent.
    Washton H
    Diagn Microbiol Infect Dis; 1989; 12(4 Suppl):229S-233S. PubMed ID: 2556239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluconazole: a new triazole antifungal agent.
    Morrow JD
    Am J Med Sci; 1991 Aug; 302(2):129-32. PubMed ID: 1897559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The triazole antifungal agents: a review of itraconazole and fluconazole.
    Bailey EM; Krakovsky DJ; Rybak MJ
    Pharmacotherapy; 1990; 10(2):146-53. PubMed ID: 2161523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients.
    Goa KL; Barradell LB
    Drugs; 1995 Oct; 50(4):658-90. PubMed ID: 8536553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antifungal drug resistance in pathogenic fungi.
    Vanden Bossche H; Dromer F; Improvisi I; Lozano-Chiu M; Rex JH; Sanglard D
    Med Mycol; 1998; 36 Suppl 1():119-28. PubMed ID: 9988500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review of the safety and efficacy of voriconazole.
    Hoffman HL; Rathbun RC
    Expert Opin Investig Drugs; 2002 Mar; 11(3):409-29. PubMed ID: 11866669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro antifungal spectrum of itraconazole and treatment of systemic mycoses with old and new antimycotic agents.
    Van Cutsem J
    Chemotherapy; 1992; 38 Suppl 1():3-11. PubMed ID: 1319313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations.
    Tucker RM; Denning DW; Hanson LH; Rinaldi MG; Graybill JR; Sharkey PK; Pappagianis D; Stevens DA
    Clin Infect Dis; 1992 Jan; 14(1):165-74. PubMed ID: 1315160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Posaconazole: clinical pharmacology and potential for management of fungal infections.
    Groll AH; Walsh TJ
    Expert Rev Anti Infect Ther; 2005 Aug; 3(4):467-87. PubMed ID: 16107193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antifungal activity of the new azole UK-109, 496 (voriconazole).
    Kappe R
    Mycoses; 1999 Dec; 42 Suppl 2():83-86. PubMed ID: 29265604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluconazole treatment of fungal infections in the immunocompromised host.
    Meunier F
    Semin Oncol; 1990 Jun; 17(3 Suppl 6):19-23. PubMed ID: 2191443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [High-dose therapy with fluconazole > or = 800 mg/day. Review].
    Penk A; Pittrow L
    Mycoses; 1997; 40 Suppl 1():33-42. PubMed ID: 9417511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose therapy with fluconazole > or = 800 mg day-1.
    Duswald KH; Penk A; Pittrow L
    Mycoses; 1997 Nov; 40(7-8):267-77. PubMed ID: 9476509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.